Previous 10 | Next 10 |
home / stock / nrix / nrix articles
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing ta...
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. Net revenue (managed) ...
U.S. stock futures were mixed this morning, with the Dow futures gaining over 50 points on Friday. Shares of Applied Digital Corporation (NASDAQ: ...
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced the pricing of its upsized underwritten...
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing ...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial resul...
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose shar...
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during T...
Presentation highlights Nurix's innovation and leadership in targeted protein modulation, including ligase inhibition Unique mechanism of act...
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal t...
SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., P...